sickling of red blood cells

FDA Approves Groundbreaking Cell-Based Gene Therapies for Sickle Cell Disease

The U.S. Food and Drug Administration (FDA) has greenlit two revolutionary cell-based gene therapies, Casgevy and Lyfgenia, marking a significant leap forward in treating sickle cell disease (SCD) for patients aged 12 and older.